LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the amount of LBH589 that can be given to
people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination
with bevacizumab is a drug combination that may stop cancer cells from growing abnormally.
LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA
approved for use in patients with colorectal cancer and has been studied extensively in other
types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but
information from other studies suggests that the combination may help prevent the growth of
the participant's tumor.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital Northwestern University Novartis University of Virginia